See also this year's filing and all EDGAR filings for this company.
PDF Report 0001382911_2017_Orexigen_Therapeutics_Inc.pdf
Logs
| warning | The EntityCommonStockSharesOutstanding does not exist | industry.us_generic | {} |
| warning | Missing logo | subcommand.report | {} |
Graph
Absolute values for 0001382911, Orexigen Therapeutics Inc
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 224,461,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 76,061,000 |
| 2 | PropertyPlantAndEquipmentNet | 1,044,000 |
| 3 | remainder_Assets | 3,023,000 |
| 4 | LiabilitiesCurrent | 65,360,000 |
| 5 | LiabilitiesNoncurrent | 0 |
| 6 | remainder_Liabilities | 0 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 118,583,000 |
| 9 | ResearchAndDevelopmentExpense | 38,023,000 |
| 10 | remainder_Expenses | -65,794,000 |
| 11 | remainder_Revenues | 33,709,000 |
| 12 | remainder_NetIncome | 32,579,000 |
| 13 | remainder_ComprehensiveNetIncome | 3,795,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 304,589,000 |
| 1 | Liabilities | 65,360,000 |
| 2 | Expenses | 90,812,000 |
| 3 | Revenues | 33,709,000 |
| 4 | StockholdersEquity | 239,229,000 |
| 5 | NetIncome | -24,524,000 |
| 6 | ComprehensiveNetIncome | -22,626,500 |
| 7 | BaseVar | 265,422,000 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | 2.70 |
| 9 | EconomicCapitalRatio | 3.49 |
Edgar->Model Mapping
Feature Distribution
